Indoco Remedies Ltd Q4 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/toi661wq4a0q06zbua461e4q.pdf

Key Takeaways


Margin Walk: The Q4 Cost Spike

Pramod Ghorpade: "We have to take the cost in this particular period, while revenues will follow in following quarters."

U.S. Business: The Bottleneck Is Cleared

Aditi Panandikar: "...against guidance, I guess, we have to be a little bit cautious now while giving guidance's because U.S. is that kind of market. If you are aware of what is happening with many of our peers, I think at Indoco, one thing you can rest upon, we are careful with our product selection and would like to play in this market to make money."

Profit-Share Income: A Recurring Stream


Domestic Business: Flat Year, Recovery Bet


International Markets: Europe and Emerging Markets


Manufacturing & Quality: Lessons from a Difficult Period

Aditi Panandikar: "It is not a child's play, and it is a very difficult manufacturing. Yes, where have we learned? Safe to assure you that we have learned more than any of our peers on what can go wrong especially matters beyond our control in the regulatory space."

Guidance & Commitments

CommitmentSpecificsTimeline
EBITDA margin recovery18% to 19% EBITDA marginFY24
India business growthMinimum 15% growthFY24 and FY25
U.S. business growth25% to 30% growthFY24
U.S. profit shareMaintain close to ₹10–12 crores per quarterQuarterly through FY24
Allopurinol U.S. revenueEasily do ₹60 crores from that single productFY24
Allopurinol German tenderAverage ₹75–80 crores per year2023 and 2024, with larger quantities than the previous tender
U.S. capacity upsideBig upside from Plant 1 availabilityBy end of 2 quarters
Combigan supply resolutionSupply should beginBy October
Brinzolamide larger SKU profit shareProfit shares start kicking in2 quarters after April launch
Combigan profit shareProfit shares start kicking in2 quarters after supply begins
Sterile plant audit classificationClassification expectedBy mid-June
Europe high-potency/oncology approvalApproval expectedEarly Q2 this year
Capex~₹125 croresComing years

Key Metrics

MetricQ4 FY23
Net revenue₹428 cr, +6.9% YoY vs ₹400.3 cr
EBITDA margin15.0% at ₹64.2 cr, vs 20.1% at ₹80 cr YoY
PAT margin6.9% at ₹29.7 cr, vs 8.9% at ₹35.6 cr YoY
EPS₹2.75, vs ₹4.38 YoY
Domestic formulation revenue₹184.5 cr, -4.3% YoY vs ₹192.9 cr
International formulation revenue₹216 cr, +14.1% YoY vs ₹189.5 cr
US business revenue₹71.3 cr, +2.6% YoY vs ₹69.6 cr
Europe revenue₹82.1 cr, +3% YoY vs ₹79.7 cr
South Africa, Australia, New Zealand revenue₹10 cr, +70% YoY vs ₹5.9 cr
IPM sales (AWACS)₹299 cr, +13.6% YoY; rank 27, market share 0.68%
India branded portfolio price increase5% to 6% during FY23
India business volume growth1% for the year gone by
US profit share₹14 cr in the quarter, spread across 2–3 products
Europe profit share₹2 cr in the quarter
Dossier incomeNil, vs over ₹17 cr in Q4 FY22
MTM forex loss₹50 lakhs, vs heavy loss in Q3
EBITDA margin guidance for FY2418% to 19%
India business growth guidance for FY24/FY25Minimum 15%
US business growth guidance for current year25% to 30%
Capex plan for FY24 and FY25~₹125 cr overall